These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1846933)

  • 1. Control and stability of ligand receptor interaction in the presence of a competitive compound.
    Tallarida RJ; Freeman KA
    Life Sci; 1991; 48(6):PL19-24. PubMed ID: 1846933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control and oscillation in ligand receptor interactions according to the law of mass action.
    Tallarida RJ
    Life Sci; 1990; 46(22):1559-68. PubMed ID: 2161974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further characterization of a control model for ligand-receptor interaction: phase plane geometry, stability, and oscillation.
    Tallarida RJ
    Ann Biomed Eng; 1990; 18(6):671-84. PubMed ID: 2177963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chaos and control in mass-action binding of endogenous compounds.
    Tallarida RJ; Freeman KA
    Ann Biomed Eng; 1994; 22(2):153-61. PubMed ID: 7915503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of receptor binding displacement curves by a nonhomologous ligand, on the basis of an equivalent competition principle.
    van Zoelen EJ
    Anal Biochem; 1992 Feb; 200(2):393-9. PubMed ID: 1321566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simulation of association curves and 'Scatchard' plots of binding reactions where ligand and receptor are degraded or internalized.
    Beck JS; Goren HJ
    J Recept Res; 1983; 3(5):561-77. PubMed ID: 6323708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin action on vascular smooth muscle involves inositol trisphosphate and calcium mobilization.
    Marsden PA; Danthuluri NR; Brenner BM; Ballermann BJ; Brock TA
    Biochem Biophys Res Commun; 1989 Jan; 158(1):86-93. PubMed ID: 2536280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha 1-adrenergic receptor mRNA level is regulated by norepinephrine in rabbit aortic smooth muscle cells.
    Izzo NJ; Seidman CE; Collins S; Colucci WS
    Proc Natl Acad Sci U S A; 1990 Aug; 87(16):6268-71. PubMed ID: 2166953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two pharmacologically distinct alpha 1-adrenoceptor subtypes in the contraction of rabbit aorta: each subtype couples with a different Ca2+ signalling mechanism and plays a different physiological role.
    Suzuki E; Tsujimoto G; Tamura K; Hashimoto K
    Mol Pharmacol; 1990 Nov; 38(5):725-36. PubMed ID: 1978244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor binding kinetics equations: Derivation using the Laplace transform method.
    Hoare SRJ
    J Pharmacol Toxicol Methods; 2018; 89():26-38. PubMed ID: 28818556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods.
    Ehlert FJ
    Mol Pharmacol; 1988 Feb; 33(2):187-94. PubMed ID: 2828914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytical determination of receptor-ligand dissociation constants of two populations of receptors from displacement curves.
    Almagor H; Levitzki A
    Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6482-6. PubMed ID: 2168549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarmesin is a partial agonist of angiotensin-II receptors in rabbit, but not in rat, aortic rings.
    Criscione L; Thomann H; Whitebread S; de Gasparo M; Kamber B
    Biochem Biophys Res Commun; 1990 Jun; 169(2):636-42. PubMed ID: 2357223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contraction velocity analysis of norepinephrine and angiotensin-II activation of vascular smooth muscle.
    Watkins RW; Davidson IW
    Eur J Pharmacol; 1980 Mar; 62(2-3):177-89. PubMed ID: 7379840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.
    Robertson MJ; Barnes JC; Drew GM; Clark KL; Marshall FH; Michel A; Middlemiss D; Ross BC; Scopes D; Dowle MD
    Br J Pharmacol; 1992 Dec; 107(4):1173-80. PubMed ID: 1467838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of competitive drug action at 5-hydroxytryptamine2 receptors in isolated rabbit aorta.
    Clancy BM; Osman R; Maayani S
    J Pharmacol Exp Ther; 1987 Jul; 242(1):108-14. PubMed ID: 3612519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of dose-response curves by effector blockade and uncompetitive antagonism.
    Pennefather P; Quastel DM
    Mol Pharmacol; 1982 Sep; 22(2):369-80. PubMed ID: 6292695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The endothelin receptor antagonist, BQ-123, inhibits angiotensin II-induced contractions in rabbit aorta.
    Webb ML; Dickinson KE; Delaney CL; Liu EC; Serafino R; Cohen RB; Monshizadegan H; Moreland S
    Biochem Biophys Res Commun; 1992 Jun; 185(3):887-92. PubMed ID: 1320879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competition between solution and cell surface receptors for ligand. Dissociation of hapten bound to surface antibody in the presence of solution antibody.
    Goldstein B; Posner RG; Torney DC; Erickson J; Holowka D; Baird B
    Biophys J; 1989 Nov; 56(5):955-66. PubMed ID: 2532552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.
    Vauquelin G; Hall D; Charlton SJ
    Br J Pharmacol; 2015 May; 172(9):2300-15. PubMed ID: 25537684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.